LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

Search

Cellectar Biosciences Inc

Closed

0.37 -19.57

Overview

Share price change

24h

Current

Min

0.35

Max

0.46

Key metrics

By Trading Economics

Employees

11

Market Stats

By TradingEconomics

Market Cap

-845K

11M

Previous open

19.94

Previous close

0.37

Cellectar Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Dec 2024, 18:44 UTC

Major Market Movers

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Peer Comparison

Price change

Cellectar Biosciences Inc Forecast

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Financials

$

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.